News
After establishing dosing and safety in Phase I, researchers will evaluate the drug's anti-tumor activity in patients with PSMA-expressing cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback